-
EP2782602
European procedure
Extract from the Register of European Patents
EP About this file: EP2782602
| EP2782602 - Nucleotide DIMS0-150 for use in the treatment of chronic active ulcerative colitis [Right-click to bookmark this link] | |||
| Former [2014/40] | METHOD FOR PREVENTION OF COLECTOMY | ||
| [2019/02] | Status | No opposition filed within time limit Status updated on 03.07.2020 Database last updated on 09.04.2026 | |
| Former | The patent has been granted Status updated on 24.05.2019 | ||
| Former | Grant of patent is intended Status updated on 14.01.2019 | Most recent event Tooltip | 03.07.2020 | No opposition filed within time limit | published on 05.08.2020 [2020/32] | Applicant(s) | For all designated states Index Pharmaceuticals AB Tomtebodavägen 23a 171 77 Stockholm / SE | [2019/13] |
| Former [2014/40] | For all designated states Index Pharmaceuticals AB Retzius väg 8 171 77 Stockholm / SE | Inventor(s) | 01 /
ADMYRE, Charlotte Läktvägen 29 S-136 73 Vendelsö / SE | 02 /
ZARGARI, Arezou Ripstigen 4 S-170 74 Solna / SE | 03 /
VON STEIN, Oliver Karlbergsvägen 8 S-194 34 Upplands Väsby / SE | 04 /
VON STEIN, Petra Karlbergsvägen 8 S-194 34 Upplands Väsby / SE | [2014/40] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2019/26] | J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | ||
| Former [2014/40] | Lundquist, Tomas Awapatent AB Box 450 86 104 30 Stockholm / SE | Application number, filing date | 12790904.2 | 23.11.2012 | [2019/26] | WO2012EP73501 | Priority number, date | EP20110190826 | 25.11.2011 Original published format: EP 11190826 | US201261595230P | 06.02.2012 Original published format: US 201261595230 P | [2014/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013076262 | Date: | 30.05.2013 | Language: | EN | [2013/22] | Type: | A1 Application with search report | No.: | EP2782602 | Date: | 01.10.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.05.2013 takes the place of the publication of the European patent application. | [2014/40] | Type: | B1 Patent specification | No.: | EP2782602 | Date: | 26.06.2019 | Language: | EN | [2019/26] | Search report(s) | International search report - published on: | EP | 30.05.2013 | Classification | IPC: | A61K48/00, A61P37/00 | [2014/40] | CPC: |
A61K31/713 (EP,US);
A61K39/0005 (US);
A61K45/06 (US);
A61P1/04 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
C12N15/117 (EP,US);
C12N2310/17 (EP,US);
C12N2310/315 (EP,US);
C12N2320/31 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/40] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | Nukleotid DIMS0-150 zur Verwendung bei der Behandlung von chronisch aktiver Colitis ulcerosa | [2019/02] | English: | Nucleotide DIMS0-150 for use in the treatment of chronic active ulcerative colitis | [2019/12] | French: | Nucleotide DIMS0-150 por son utilisation dans le traitement de la colite ulcéreuse active chronique | [2019/02] |
| Former [2014/40] | VERFAHREN ZUR VORBEUGUNG EINER DICKDARMRESEKTION | ||
| Former [2014/40] | METHOD FOR PREVENTION OF COLECTOMY | ||
| Former [2014/40] | PROCÉDÉ DE PRÉVENTION DE LA COLECTOMIE | Entry into regional phase | 03.06.2014 | National basic fee paid | 03.06.2014 | Designation fee(s) paid | 03.06.2014 | Examination fee paid | Examination procedure | 03.06.2014 | Amendment by applicant (claims and/or description) | 03.06.2014 | Examination requested [2014/40] | 11.08.2015 | Despatch of a communication from the examining division (Time limit: M04) | 07.12.2015 | Reply to a communication from the examining division | 04.12.2018 | Cancellation of oral proceeding that was planned for 29.01.2019 | 15.01.2019 | Communication of intention to grant the patent | 29.01.2019 | Date of oral proceedings (cancelled) | 13.05.2019 | Fee for grant paid | 13.05.2019 | Fee for publishing/printing paid | 13.05.2019 | Receipt of the translation of the claim(s) | Divisional application(s) | EP19173912.7 / EP3556403 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 11.08.2015 | Opposition(s) | 03.06.2020 | No opposition filed within time limit [2020/32] | Fees paid | Renewal fee | 05.11.2014 | Renewal fee patent year 03 | 02.11.2015 | Renewal fee patent year 04 | 10.11.2016 | Renewal fee patent year 05 | 13.11.2017 | Renewal fee patent year 06 | 14.11.2018 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI] WO2007004977 (INDEX PHARMACEUTICALS AB et al.) [X] 1-8,13,14,16-28,33,34,36-48,53,54,56-60 * claims 1,27,15-17,41-43 * * page 22 - page 23 * * page 18, line 12 - line 15 * * page 13, paragraph 4 * * examples 5,6 *[I] 9-15,29-35,49-55 | [X] WO2007004979 (INDEX PHARMACEUTICALS AB et al.) [X] 1-7,13,14,17-27,33,34,37-47,53,54,57-60 * claims 1,24,31,12-14,35-37 * * page 26, line 7 - line 9; examples 7,8 * * page 13, paragraph 4 * * examples 7,8 * | [XI] THOMSON REUTERS INTERGITY: "DIMS0150 as rectal therapy in steroid refractory ulcerative colitis? results from a placebo controlled randomised trial", INTERNET CITATION, 21 November 2009 (2009-11-21), XP002670456, Retrieved from the Internet | [I] JUDY H. CHO ET AL: "Recent Insights Into the Genetics of Inflammatory Bowel Disease", GASTROENTEROLOGY, vol. 140, no. 6, 1 May 2011 (2011-05-01), pages 1704 - 1712.E2, XP055020412, ISSN: 0016-5085, DOI: 10.1053/j.gastro.2011.02.046 [I] 9-15,29-35,49-55 * the whole document * DOI: http://dx.doi.org/10.1053/j.gastro.2011.02.046 | [A] VON STEIN PETRA: "Inflammatory bowel disease classification through multigene analysis: fact or fiction?", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS JAN 2009 LNKD- PUBMED:19099342, vol. 9, no. 1, January 2009 (2009-01-01), pages 7 - 10, XP002670457, ISSN: 1744-8352 [A] 9-15,29-35,49-55 * the whole document * * page 8, paragraph 3 * DOI: http://dx.doi.org/10.1586/14737159.9.1.7 | by applicant | EP0468520 | WO9602555 | WO9728259 | WO9816247 | WO2007004977 | WO2007004979 | US6339068 | US6406705 | US6426334 | US6426336 | US5635377 | US5366878 | BAUER M; REDECKE V; ELLWART JW; SCHERER B; KREMER JP; WAGNER H; LIPFORD GB.: "Bacterial CpG-DNA triggers activation and maturation of human CD11 c-, CD123+ dendritic cells", J IMMUNOL, vol. 166, 2001, XP002979100 | CHO JH; BRANT SR: "Recent insights into the genetics of inflammatory bowel disease", GASTROENTEROLOGY, vol. 140, 2011, pages 1704 - 1712 | COSNES J.: "Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD", DIG DIS, vol. 28, 2010, pages 411 - 7 | FILIPPI J; ALLEN PB; HEBUTERNE X; PEYRIN-BIROULET L.: "Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis?", A SYSTEMATIC REVIEW. CURR DRUG TARGETS, 5 April 2011 (2011-04-05) | FERRANTE M; DECLERCK S; DE HERTOGH G ET AL.: "Outcome after proctocolectomy with ileal poucheanal anastomosis for ulcerative colitis", INFLAMM BOWEL DIS, vol. 14, 2008, pages 20 - 8 | GEBOES K; RIDDELL R; OST A; JENSFELT B; PERSSON T; LOFBERG R.: "A reproducible grading scale for histological assessment of inflammation in ulcerative colitis (comment", GUT, vol. 47, 2000, pages 404 - 409 | HELLER F; FUSS IJ; NIEUWENHUIS EE; BLUMBERG RS; STROBER W.: "Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13- producing NK-T cells", IMMUNITY, vol. 17, 2002, pages 629 - 638, XP009082045, DOI: doi:10.1016/S1074-7613(02)00453-3 DOI: http://dx.doi.org/10.1016/S1074-7613(02)00453-3 | JAHN-SCHMID B; WIEDERMANN U; BOHLE B; REPA A; KRAFT D; EBNER C.: "Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1 , the major birch pollen allergen.", J ALLERGY CLIN IMMUNOL., vol. 104, no. 5, November 1999 (1999-11-01), pages 1015 - 23, XP027421057, DOI: doi:10.1016/S0091-6749(99)70083-7 DOI: http://dx.doi.org/10.1016/S0091-6749(99)70083-7 | KLINMAN DM; BARNHART KM; CONOVER J.: "CpG motifs as immune adjuvants", VACCINE, vol. 17, no. 1, January 1999 (1999-01-01), pages 19 - 25, XP004139028, DOI: doi:10.1016/S0264-410X(98)00151-0 DOI: http://dx.doi.org/10.1016/S0264-410X(98)00151-0 | KRUG A; TOWAROWSKI A; BRITSCH S; ROTHENFUSSER S; HORNUNG V; BALS R; GIESE T; ENGELMANN H; ENDRES S; KRIEG AM: "Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12", EUR J IMMUNOL., vol. 31, no. 10, October 2001 (2001-10-01), pages 3026 - 37, XP002976488, DOI: doi:10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H DOI: http://dx.doi.org/10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H | LANGHOLZ E; MUNKHOLM P; DAVIDSEN M; BINDER V.: "Course of ulcerative colitis: analysis of changes in disease activity over years", GASTROENTEROLOGY, vol. 107, 1994, pages 3 - 11 | RACHMILEWITZ D: "Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.", BMJ, vol. 298, 1989, pages 82 - 86, XP008063079 | RIEGLER G; TARTAGLIONE MT; CARRATU R ET AL.: "Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis", DIG DIS SCI, vol. 45, 2000, pages 462 - 5 | RUBIN DT; SIEGEL CA; KANE SV ET AL.: "Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey", INFLAMM BOWEL DIS., vol. 15, 2009, pages 581 - 588 | THOMPSON AI; LEES CW.: "Genetics of ulcerative colitis", INFLAMM BOWEL DIS., 2011, pages 831 - 48 | SCHMITZ H; BARMEYER C; FROMM M ET AL.: "Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis", GASTROENTEROLOGY, vol. 116, 1999, pages 301 - 9 | SJOBERG M; WALCH A; MESHKAT M ET AL.: "Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study", INFLAMM BOWEL DIS, 2011 | TIGHE H; TAKABAYASHI K; SCHWARTZ D; MARSDEN R; BECK L; CORBEIL J; RICHMAN DD; EIDEN JJ JR; SPIEGELBERG HL; RAZ E.: "Conjugation of protein to immunostimulatory DNA results in a rapid, long- lasting and potent induction of cell-mediated and humoral immunity", EUR J IMMUNOL., vol. 30, no. 7, July 2000 (2000-07-01), pages 1939 - 47, XP002681594, DOI: doi:10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-# DOI: http://dx.doi.org/10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-# | TOKUNAGA T; YANO 0; KURAMOTO E; KIMURA Y; YAMAMOTO T; KATAOKA T; WEINRYB RM; GUSTAVSSON JP; LILJEQVIST L ET AL.: "A prospective study of the quality of life after pelvic pouch operation.", J AM COLL SURG, vol. 180, 1995, pages 589 - 95 | TRIANTAFILLIDIS JK; MERIKAS E; GEORGOPOULOS F.: "Current and emerging drugs for the treatment of inflammatory bowel disease", DRUG DES DEVEL THER, vol. 5, 2011, pages 185 - 210 | TURNER D; WALSH CM; STEINHART AH; GRIFFITHS AM: "Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta- regression", CLIN GASTROENTEROL HEPATOL, vol. 5, 2007, pages 103 - 110, XP005920786, DOI: doi:10.1016/j.cgh.2006.09.033 DOI: http://dx.doi.org/10.1016/j.cgh.2006.09.033 | WILHELM SM; MCKENNEY KA; RIVAIT KN; KALE-PRADHAN PB.: "A review of infliximab use in ulcerative colitis", CLIN THER, vol. 30, 2008, pages 223 - 30, XP022526750, DOI: doi:10.1016/j.clinthera.2008.02.014 DOI: http://dx.doi.org/10.1016/j.clinthera.2008.02.014 | WINE E; OSSA JC; GRAY-OWEN SD; SHERMAN PM.: "Adherent-invasive Escherichia coli target the epithelial barrier", GUT MICROBES, vol. 1, 2010, pages 80 - 84 | WEINRYB RM; GUSTAVSSON JP; LILJEQVIST L ET AL.: "A prospective study of the quality of life after pelvic pouch operation.", J AM COLL SURG, vol. 180, 1995, pages 589 - 95 | XAVIER RJ; PODOLSKY DK: "Unravelling the pathogenesis of inflammatory bowel disease", NATURE, vol. 448, 2007, pages 427 - 434, XP055497745, DOI: doi:10.1038/nature06005 DOI: http://dx.doi.org/10.1038/nature06005 | YAMAMOTO S.: "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells", MICROBIOL LMMUNOL., vol. 36, no. 1, 1992, pages 55 - 66, XP008024955 |